Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.41 |
| ▸ | HRH2 | P25021 | 11/20 | 0.41 |
| ▸ | HRH1 | P35367 | 11/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6967950 | 0.99 | HRH3 (0.40) | HRH3HRH2HRH1SMN1; SMN2PPARD | |
| SCHEMBL6965997 | 0.86 | LMNA (0.38) | HRH3 | |
| Hydrochloric Acid SCHEMBL6968897 | 0.85 | SIGMAR1 (0.38) | HRH3 | |
| SCHEMBL6962031 | 0.76 | SLC6A2 (0.42) | ICMT | |
| SCHEMBL6960436 | 0.74 | LMNA (0.40) | — | |
| SCHEMBL2338542 | 0.73 | SLC6A2 (0.57) | HRH3HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL6849761 | 0.72 | ADRA1A (0.36) | — | |
| SCHEMBL6967165 | 0.71 | KDM1A (0.39) | PPARDPPARA | |
| SCHEMBL6963118 | 0.71 | LTA4H (0.46) | HRH1 | |
| SCHEMBL6962525 | 0.71 | ADRA1A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | disclosed |
| EP-1268483-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-20010049385-A1 | Imidazo heterocyclic compounds | HIGH POINT PHARMACEUTICALS, LLC | 2001-12-06 | — | — | US | disclosed |
| WO-2001068651-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049385-A1 | Imidazo heterocyclic compounds | HRH4, HRH3, HRH2 | HRH3 2/4885HRH2 3/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.